What Enanta Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 9 |
| Total trades | 1 | 36 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 61,993 |
| Disposed | 1,467 | 39,826 |
| Net activity | −1,467 | +22,167 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Rottinghaus Scott T. | Chief Medical Officer | Aug 08 | Withheld — tax / exercise cost · F | −1,467 | $13.34 | −$19.6K | 23,787 |
| Luly Jay R. | President and CEO | Feb 12 | Withheld — tax / exercise cost · F | −6,155 | $14.25 | −$87.7K | 871,871 |
| Luly Jay R. | President and CEO | Feb 12 | Grant / award · A | +15,200 | — | — | 878,026 |
| Luly Jay R. | President and CEO | Feb 12 | Grant / award · A | +4,800 | — | — | 862,826 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Feb 12 | Withheld — tax / exercise cost · F | −3,257 | $14.25 | −$46.4K | 33,925 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Feb 12 | Grant / award · A | +4,987 | — | — | 37,182 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Feb 12 | Grant / award · A | +1,575 | — | — | 32,195 |
| Or Yat Sun | Chief Scientific Officer | Feb 12 | Withheld — tax / exercise cost · F | −3,413 | $14.25 | −$48.6K | 374,854 |
| Or Yat Sun | Chief Scientific Officer | Feb 12 | Grant / award · A | +5,225 | — | — | 378,267 |
| Or Yat Sun | Chief Scientific Officer | Feb 12 | Grant / award · A | +1,650 | — | — | 373,042 |
| Luu Brendan | Chief Business Officer | Feb 12 | Withheld — tax / exercise cost · F | −3,257 | $14.25 | −$46.4K | 41,634 |
| Luu Brendan | Chief Business Officer | Feb 12 | Grant / award · A | +4,987 | — | — | 44,891 |
| Luu Brendan | Chief Business Officer | Feb 12 | Grant / award · A | +1,575 | — | — | 39,904 |
| Kowalsky Matthew Paul | Chief Legal Officer | Feb 12 | Withheld — tax / exercise cost · F | −1,902 | $14.25 | −$27.1K | 3,591 |
| Kowalsky Matthew Paul | Chief Legal Officer | Feb 12 | Grant / award · A | +4,175 | — | — | 5,493 |
| Kowalsky Matthew Paul | Chief Legal Officer | Feb 12 | Grant / award · A | +1,318 | — | — | 1,318 |
| Rottinghaus Scott T. | Chief Medical Officer | Feb 12 | Withheld — tax / exercise cost · F | −3,413 | $14.25 | −$48.6K | 25,254 |
| Rottinghaus Scott T. | Chief Medical Officer | Feb 12 | Grant / award · A | +5,225 | — | — | 28,667 |
| Rottinghaus Scott T. | Chief Medical Officer | Feb 12 | Grant / award · A | +1,650 | — | — | 23,442 |
| Luly Jay R. | President and CEO | Dec 05 | Sale for tax withholding · S | −4,743 | $14.23 | −$67.5K | 858,026 |
Loading...
